Claim Ownership

Author:

Subscribed: 0Played: 0
Share

Description

 Episodes
Reverse
Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.As a function uniquely positioned to address evolving market dynamics, how can Medical Affairs prepare for 2030 and beyond? In this first episode, hear from Josh Ziel, Executive Vice President, Scientific Services at Syneos Health Communications as he unpacks how we can get beyond incremental improvements to really be bold and think forward as we bring Medical Affairs into the future.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!   We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
The clinical research enterprise faces a clear and present personnel shortage, creating inefficiencies for clinical trial sponsors and contract research organizations, many of whom find themselves in a constant recruitment cycle for qualified clinical research associates (CRAs) in a hyper-competitive job market. While industry has traditionally recruited for these roles from healthcare and scientific programs or settings, we are now seeing a shift from requiring that specific, role-based experience to a more foundational competency-based model. This means potentially looking outside of those traditional sources. But how to we find, recruit and train this next generation?Jennifer Sozio, Senior Vice President, Clinical Operations and Audra Holleman, Vice President, Clinical Development at Syneos Health discuss the new profile of CRA candidates, challenges and opportunities for recruitment in the current market, and how to train and prepare a growing pool of new CRA resources focused on quality, project delivery and commitment to advancement.Learn more about the Syneos Health Clinical Training Institute here. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Getting Access

Getting Access

2022-04-2721:13

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market. Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for access and what really matters to payers in the long run.For more on value and access in biopharma, check out:How Competition Affects Market Access for Rare Disease Therapeutics, Part 1How Competition Affects Market Access for Rare Disease Therapeutics, Part 2Future-Forward Planning: What Drug and Device Manufacturers Need to Know About Preventive Drug Lists2021 Update: Non-Personal Promotion: What Do Payers Want?​The Other Path to Access: Strategies for Direct Employer Engagement​The Syneos Health Podcast: Trade and Distribution in Pharma: It's Complicated​What to Expect on Drug Pricing in the Democratic Trifecta​ If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Nobody thinks about epilepsy as a rare disease. But epilepsy syndromes actually make up a large portion of CNS rare diseases. And while progress has been made in developing therapies that treat the symptoms of epilepsy, the true underlying causes can be difficult to pinpoint and treat. But progress is being made, and Nermina Nakas, MD, MPH and Jane Williams, MD, MPH, Executive Medical Directors in CNS at Syneos Health – and contributors to the book Rare Disease Drug Development: Clinical, Scientific, Patient and Caregiver Perspectives – join Jeff Stewart to discuss recent developments in rare disease epilepsy clinical trials, what they have learned and what drug developers need to know about treating young patients with neurological rare diseases.For more on the topics covered in this episode, be sure to check out:Innovation Perspectives in Rare Disease Drug DevelopmentThe Syneos Health Podcast: Navigating the Rare Disease LandscapeThe Syneos Health Podcast: Mental Health in Rare DiseaseRare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver PerspectivesIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
The Placebo Effect

The Placebo Effect

2022-03-2323:36

Did you know that over half of doctors leverage the placebo effect in treating patients? Placebo can be a powerful tool in medical practice—and in clinical research.Veeru Goli, MD, Vice President, Medical and Scientific Management, Syneos Health, unpacks the case for use of placebo in clinical treatment, and if applied properly, how the placebo effect can help in clinical trials.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Life with a rare disease can have infinite milestones, setbacks, traumas and triumphs—all likely to be interlaced with a variety of factors that can influence mental health and quality of life.In fact, according to Dr. Raymond A. Huml in the February 2020 Journal for Clinical Studies, psychological symptoms are estimated to affect 75% of rare disease patients. Whether the cause is from the physical disease or dynamics surrounding it, it is time to remove the stigma around talking about mental health, understand the unique challenges of this community, and drive support and solutions to address them. In advance of Rare Disease Day 2022, Keri McDonough, VP, Head of the Patient Voice Consortium and Michelle Bailey, MD, Senior Medical Director at Syneos Health, sit down with host Jeff Stewart to discuss the impact of mental health on the rare disease community.To find the resources discussed on the podcast:Our OdysseyNew York Times: I’m Haunted by Sisters With Sickle Cell: Two Thrived. Two SufferedRare Disease Day 2022: Collaborating to Make Mental Health in Rare Disease Stigma-Free  For more on the topics covered in this episode, be sure to check out:Innovation Perspectives in Rare Disease Drug DevelopmentThe Syneos Health Pocast: Navigating the Rare Disease LandscapeRare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver PerspectivesIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Patients with rare diseases and their caregivers face many unique challenges along the road to diagnosis, treatment and—ultimately—optimized quality of life. With all of the complex information and systems out there, the landscape can be difficult to navigate. Where can they go for guidance?Ray Huml, Vice President, Medical & Scientific Strategy and Head of the Rare Disease Consortium at Syneos Health—and editor of the recently published book Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives—returns to the podcast to discuss his dual experience as a scientist and caregiver, what drove him to create two informative books, and insights on cracking the code to reimbursement in rare disease.For more on the topics covered in this episode, be sure to check out:How Competition Affects Market Access for Rare Disease Therapeutics – Part IHow Competition Affects Market Access for Rare Disease Therapeutics — Part IIThe Syneos Health Podcast: Real World Evidence and Rare DiseasesInnovation Perspectives in Rare Disease Drug DevelopmentFind the books discussed in this episode:Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver PerspectivesMuscular Dystrophy: A Concise GuideIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
The COVID-19 pandemic had had a considerable impact on biotech and pharma services outsourcing, as companies struggled to overcome supply chain issues in production, manufacturing and talent. This held true not only from an R&D perspective, but throughout the product lifecycle as biopharma continued to bring therapies to an evolving market.Michael Jimmink, Vice President, FSP 360 and Jim Reidy, Vice President, Deployment Solutions from Syneos Health discuss ways to navigate business continuity through strategic outsourcing, including why, how and when to consider outsourcing solutions, as well as ways to utilize fit-for-purpose resourcing while maintaining strategic oversight.For more on the topics covered in this episode, be sure to check out:2022 Health Trends: Insights for Industry Change AgentsAre You Assembling the Right Team for Commercial Success?FSP 360: A Flexible, Customizable Solution for Your Outsourcing NeedsOutsourcing R&D in Today’s MarketIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
COVID-19 has accelerated adoption of virtual engagement across pharma – but many of these strategies have already been proven over and over again long before the pandemic. The key difference is, what started as a complement to traditional commercialization tactics is now an established best practice and has been core to an inevitable transformation in the pharmaceutical industry. Out of this, the Virtual Sales Organization was born.Mike Minschwaner, Senior Director and Amy Jamison, Senior Vice President of the Syneos Health Engagement Center discuss the evolution and rationale behind the Virtual Sales Organization, where, when and how it is appropriate to incorporate into sales strategy and the non-traditional skillset required for reps to succeed.For more on the Virtual Sales Organization, check out our on-demand webinar and white paper.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
What if you had 30 years of longitudinal data, from thousands of HCPs across 30 specialties, on how and why health care practitioners prescribe therapies, and where and how they prefer to receive information on those therapies – or even how a major event, like a pandemic, impacted those behaviors? You would have powerful insights that point the way to new opportunities to engage customers, seize white space in the market and understand where your competitors are engaging.In this episode of the Syneos Health Podcast, Cameron Thompson, Executive Vice President of AnswerSuite, a Syneos Health® company, discusses the value of longitudinal data, the impact COVID-19 has had on physician preferences and how companies can leverage this information to right-size their promotional efforts with agility in an ever-changing market.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
This week, the US Food and Drug administration approved the first COVID-19 vaccine. But will this help accelerate the vaccination effort? The US Surgeon General gave a public warning recently: "Health misinformation is an urgent threat to public health. It can cause confusion, sow mistrust, and undermine public health efforts, including our ongoing work to end the COVID-19 pandemic.” Also this week, the Kaiser Family Foundation released a report saying the number one reason for those who changed their minds and got vaccinated, the single thing that worked best, was talking with family.In this Syneos Short, host Jeff Stewart debunks the most common myths circulating about COVID-19 vaccines and provides tips for guiding friends and family as they wade through a sea of information.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.EPISODE REFERENCES:AP News (SM-102)YouGov.com poll - why won't Americans get vaccinatedCDC VAERS and vaccine risksNature hydroxychloroquine The Guardian Ivermectin paperNEJM  COVID-19 vaccines reduce transmissionGizmodo,  Medium COVID-19 vaccine death claims retractedNBC News unvaccinated hospitalizationsAP News COVID-19 deaths among unvaccinated
In this episode of the Syneos Health Podcast: 2021 Health Trends Edition, we welcome Dr. George Li, Vice President, and General Manager in clinical solutions for mainland China, Hong Kong and Taiwan. Together with podcast host and Managing Director, Omnichannel Strategy, Leigh Householder, he discusses the rapid and dramatic growth occurring in the Chinese pharmaceutical and biotech market.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.RELATED CONTENTChina: The Pace Car of ChangeSyneos Health Podcast: China vs. Cancer2021 Health Trends: Field Force of the Future 
In this episode of the Syneos Health Podcast: 2021 Health Trends Edition, we discuss how to empower and amplify critical field teams as access and engagement evolve and change with the ‘new normal’ of a post-pandemic world. Listen and learn as Ryan Maglione, SVP, Global Commercial Talent at Syneos Health shares his latest thinking with trends expert, podcast host and Managing Director, Omnichannel Strategy, Leigh Householder.Learn More About Commercial Recruiting Solutions from Syneos Health. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.RELATED CONTENTForming the Future Field Omnichannel Experience Virtual Pharma
In this episode of the Syneos Health Podcast: 2021 Health Trends Edition, we share the latest thinking on the potential for our industry to make healthcare interactions and communications more personal and useful. Many life sciences organizations are quickly moving into that world of right person, right message, right moment messaging and scaling internal expertise and external partnership to move from one-to-one messaging to synchronized personal/nonpersonal communications to truly optimized engagement.Listen and learn from Syneos Health experts, Leigh Householder, Managing Director, Omnichannel Strategy, Howard Brock, Senior Managing Director, Customer Engagement/Consulting, Alex Brock, Managing Director, Omnichannel (EU) and Dr. Annah Sclafani, Data Scientist. Curious where your organization sits on the omnichannel maturity curve? Click here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.RELATED CONTENTHarnessing Big Data to Accelerate Trial RecruitmentOmnichannel Maturity2021 Health Trend Edition: Remote Care in 2021 and Beyond
Storytelling in Pharma

Storytelling in Pharma

2021-07-0726:24

A great story creates a connection, elicits feelings of compassion and empathy and can ultimately influence behavior. The rise of digital platforms have enabled richer, deeper storytelling, driving a greater desire for sharing and connection. How can biopharma companies better leverage their own stories to build trust and engagement with their audiences?John Reid, Executive Creative Director and Jeanine O’Kane, President, Public Relations at Syneos Health Communications discuss the evolution of storytelling, the impact of COVID-19 on how we communicate – and the critical importance of transparency and authenticity in the biopharma industry.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
When the pandemic took hold, practices and research sites limited physical access to protect people while health systems and industry partners moved to rapidly scale digital and voice channels to maximize patient connectivity. Regulators and payers joined the cause to reduce friction and fuel reimbursement. As that immediacy and urgency fade, there are changed expectations among healthcare providers and patients alike that pivot off a connection, not an office or site. In this episode of the 2021 Health Trends Podcast Miniseries, Leigh Householder, Syneos Health resident trends expert and Managing Director, Omnichannel Strategy, discusses how the rise, fall and reset of remote monitoring and commercial telemedicine will largely shape the future of care and drive how life sciences leaders engage and support patients and prescribers. Guests include Syneos Health experts AJ Triano, SVP, Customer Experience Strategy and Jodi Scarbrough, VP, Strategy and Innovation.Learn more about our 2021 Health Trends here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 
Virtual Pharma

Virtual Pharma

2021-06-3024:20

At the beginning of the COVID-19 pandemic and in direct response to government advisories limiting nonessential travel, healthcare practitioners (HCPs) were quick to adopt digital platforms for engaging with pharma sales reps.  And interestingly, it appears that these virtual engagements are actually increasing the amount of time HCPs spend with these reps. Now, as we move past this transformative time, the future that is emerging is neither fully face-to-face nor solely digital-dedicated.Bryan Roman, Executive Vice President of Creative Technology and Stephan Saba, Senior Vice President of Customer Experience at Syneos Health talk about innovations in technology that can better enable interactions between sales reps and their customers in a post-pandemic world.For more on the impact COVID-19 has had on physicians’ engagement with telemedicine platforms and field force teams, check out our recent report.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Right now, millions of patients are being dosed with vaccines for COVID-19, which have had accelerated development timelines in order to provide emergency use. This is a first in our industry, and it presents safety monitoring challenges for pharmaceutical companies managing an unprecedented volume of data to ensure that the benefits to patients outweigh the risks. How can they keep up – now, and in the future?Carol Aliyar, Executive Vice President, Global Head of Safety and Pharmacovigilance at Syneos Health, discusses the impact the COVID-19 vaccine rollout on current safety monitoring processes, how biopharma needs to adjust going forward, and why the human element remains a critically important part of the solution.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Lifecycle Management

Lifecycle Management

2021-05-0514:48

It is a common misconception in the biopharmaceutical industry that lifecycle management is really meant for the end of a product’s life, generally at the point where exclusivity is lost and generic competition erodes sales and, ultimately, the value of the brand. According to Tim Arendt, Managing Director in the Commercial Advisory Group of Syneos Health Consulting, if done right, a lifecycle management plan developed early will actually pay off in spades in the end. Here, he discusses the importance of lifecycle management in biopharma and how companies can – and should – leverage this tool to ensure their products will reach their full potential, throughout their lifecycle.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Source Document Review and Source Data Verification have been the gold standard for ensuring data quality and patient safety for more than 30 years.  This review and verification process covers a wide range of material related to study subjects including anything from consent forms and medical histories to lab results and personal diary entries and beyond, consuming a significant amount of time and budget.  In recent years, we’ve seen a drive to find ways to make clinical trial monitoring more effective and cost efficient, especially with the growing use of technologies such as Electronic Data Capture (EDC) systems.  Audra Holleman, Vice President, Clinical Monitoring and Nicole Stansbury, Vice President, Global Monitoring at Syneos Health, discuss the evolution of what once was a manual and time consuming process of sifting through potentially thousands of pieces of material to a far more efficient and strategic approach driven by advancements of the digital age.Listen to Nicole Stansbury discuss the importance of risk-based monitoring previously on the podcast in our CORONAVIRUS SPECIAL EDITION, Episode 7: Continuity in Clinical Trials.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
Comments 
Download from Google Play
Download from App Store